DDInter927 DDInter1118
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers).
Magnesium hydroxide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Quazepam
Magnesium hydroxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diclofenamide
Magnesium hydroxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deutetrabenazine
Magnesium hydroxide {u} may lead to a major life threatening interaction when taken with {v} Erdafitinib
Magnesium hydroxide {u} may lead to a major life threatening interaction when taken with {v} Tolevamer
Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Quazepam
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Magnesium hydroxide may lead to a major life threatening interaction when taken with Erdafitinib
Magnesium hydroxide may lead to a major life threatening interaction when taken with Tolevamer